Paclitaxel-Coated Balloon Angioplasty vs. Plain Balloon Dilation for the Treatment of Failing Dialysis Access:<b>6-Month Interim Results From a Prospective Randomized Controlled Trial</b>

Κατσάνος, Κωνσταντίνος; Karnabatidis, Dimitris; Kitrou, Panagiotis; Spiliοpoulos, Stavros; Christeas, Nikolaos; Siablis, Dimitris

doi:10.1583/11-3690.1

Cited by 153 publications

(140 citation statements)

References 30 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Interdisciplinary planning is therefore decisive for ensuring that the placement of proximal replacement vascular access is not prevented. In a randomized study including 40 patients with stenoses in the venous branch, a higher primary patency rate (70 %) compared to conventional PTA (25 %) was observed 6 months after use of a drug-coated balloon [12]. However, there is currently no long-term data for this study.…”

Section: Stenosis Of the Vascular Access Veinmentioning

confidence: 79%

“…Elastic or rigid stenoses can be treated by conventional PTA and stent implantation as well as by cutting balloon, for example [10,11]. To prevent recurrent stenoses, the use of drug-coated balloons is increasingly being reported [12,13]. There are currently no randomized studies or even larger case series showing a superior long-term patency rate for endovascular brachytherapy [14,15] and cryoplasty [16].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and Treatment of Insufficient Dialysis Vascular Access

Kamper

Faizy²,

Haage³

2015

Fortschr Röntgenstr

View full text Add to dashboard Cite

A wide variety of diagnostic and minimally invasive modalities is currently available to radiologists for providing sufficient medical care for dialysis patients. In addition to clinical examination, ultrasound is the first line imaging method in suspected dialysis vascular access dysfunction. The percutaneous approach is the primarily recommended therapeutic option in many cases. This article reviews the current diagnostic and therapeutic methods in dialysis vascular access insufficiency. Key Points: ??Vascular access dysfunction is often elicited by stenosed vessels, which are regularly associated with concomitant thrombosis. ??Stenoses are commonly observed in the anastomosis, vascular access vein and also in the central venous system. ??Beside the clinical examination, sonography is the diagnostic method of first choice. ??Percutaneous balloon dilatation frequently is the first treatment option. Citation Format: ??Kamper L, Faizy TD, Haage P. Diagnosis and Treatment of Insufficient Dialysis Vascular Access. Fortschr R?ntgenstr 2015; 187: 360???371

show abstract

Section: Stenosis Of the Vascular Access Veinmentioning

confidence: 79%

mentioning

confidence: 99%

Diagnosis and Treatment of Insufficient Dialysis Vascular Access

Kamper

Faizy²,

Haage³

2015

Fortschr Röntgenstr

View full text Add to dashboard Cite

show abstract

“…The smooth muscle cells in the veins are more responsive to effects of anti-proliferative agents as compared to their arterial counterparts [12]. A recent randomized controlled trial showed improved patency of failing hemodialysis vascular access when paclitaxel coated balloon angioplasty was used for vascular stenosis with cumulative target lesion primary patency of 70% with drug coated balloon versus 25% with conventional balloon angioplasty (HR 0.30, 95% CI 0.12 to 0.71, p < 0.006) [13]. Massmann et al retrospectively reviewed 27 patients with hemodialysis fistula associated central venous stenosis and found that paclitaxel coated balloon angioplasty showed statistically significant longer freedom period from target vessel revascularization compared to conventional balloon angioplasty [14].…”

Section: Discussionmentioning

confidence: 99%

Percutaneous Management of Non Malignant Superior Vena Cava Syndrome Using IN.PACT Paclitaxel Coated Balloon

Iftikhar¹,

Gajo²,

Fisher³

et al. 2017

AJCTS

View full text Add to dashboard Cite

Superior Vena Cava (SVC) syndrome is an uncommon but known complication of Implantable Cardioverter Defibrillator (ICD) and pacemaker lead placement. In general 0.2 to 3% of all implants are associated with symptomatic SVC stenosis. Stent placement is a viable option for benign SVC syndrome in the absence of indwelling pacing leads. The risk of perforation and lead fracture increases when large numbers of leads are present chronically. We describe here a case of patient with SVC syndrome secondary to chronic ICD and pacemaker lead placement and a novel use of IN.PACT tm paclitaxel drug coated balloon to treat the SVC obstruction with a favorable clinical result.

show abstract

“…A recent randomized controlled trial is evaluating the outcomes of angioplasty with a paclitaxel-coated balloon (PCB) versus plain balloon angioplasty (58). Six-month interim data from this study reported that cumulative target lesion primary patency at 6 months, defined as angiographic visualization of a patent lesion or circuit with ,50% angiographic restenosis and no need for any repeat procedures during the follow-up period, was significantly higher after PCB (70% in PCB group versus 25% in balloon angioplasty group; P,0.001) (58).…”

Section: Drug-coated Balloonsmentioning

confidence: 99%

Novel Paradigms for Dialysis Vascular Access

Lee

2013

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryVascular access dysfunction is a major cause of morbidity and mortality in hemodialysis patients. The most common cause of vascular access dysfunction is venous stenosis from neointimal hyperplasia within the perianastomotic region of an arteriovenous fistula and at the graft-vein anastomosis of an arteriovenous graft. There have been few, if any, effective treatments for vascular access dysfunction because of the limited understanding of the pathophysiology of venous neointimal hyperplasia formation. This review will (1) describe the histopathologic features of hemodialysis access stenosis; (2) discuss novel concepts in the pathogenesis of neointimal hyperplasia development, focusing on downstream vascular biology; (3) highlight future novel therapies for treating downstream biology; and (4) discuss future research areas to improve our understanding of downstream biology and neointimal hyperplasia development.

show abstract

Paclitaxel-Coated Balloon Angioplasty vs. Plain Balloon Dilation for the Treatment of Failing Dialysis Access:6-Month Interim Results From a Prospective Randomized Controlled Trial

Abstract: PCB angioplasty improves patency after angioplasty of venous stenoses of failing vascular access used for dialysis.

Cited by 153 publications

References 30 publications

Diagnosis and Treatment of Insufficient Dialysis Vascular Access

Diagnosis and Treatment of Insufficient Dialysis Vascular Access

Percutaneous Management of Non Malignant Superior Vena Cava Syndrome Using IN.PACT Paclitaxel Coated Balloon

Novel Paradigms for Dialysis Vascular Access

Contact Info

Product

Resources

About